Investment Fund

With collective lifetime investments in over 50 companies and successful exits, 215 Capital partners have launched a newly-formed Togo PHL Fund I with a mandate to deploy $100MM in new investments focusing on disruptive early and mid-stage companies in the pharmaceutical, healthcare and life sciences sectors. The Togo PHL Fund aims to invest in the next generation of industry-defining companies by leading or co-leading funding rounds to offer capital growth investments for biopharmaceutical, medical device, diagnostic, and technology-enabled healthcare service specialists. We deliver investor value by deploying our deep clinical, commercial and operational domain expertise to promising companies that need access to capital, global network, resources and infrastructure to develop innovative and cutting-edge therapeutic solutions, technologies, tools, and services that address the greatest areas of unmet medical need. Our globally-integrated team operates under a single investment platform to deliver hands-on domain expertise, capital, and resources to help businesses identify macro trends and growth opportunities across economic conditions and geographies.

We are stage agnostic but innovation devout, funding both seed and later-stage investments in companies engaged in research, development, production, or distribution of products or services related to health and personal care, medicine, or pharmaceuticals.